甘李药业甘精胰岛素注射液获欧盟委员会上市许可

Core Viewpoint - Ganli Pharmaceutical has received marketing authorization from the European Commission for its insulin product, Ondibta®, which is intended for the treatment of diabetes in adults, adolescents, and children aged 2 years and older [1] Group 1 - Ganli Pharmaceutical and its wholly-owned subsidiary in Europe have been granted approval for Ondibta® in the EU, Iceland, Liechtenstein, and Norway [1] - Ondibta® is a long-acting insulin that requires subcutaneous injection once daily, providing a stable blood glucose control for 24 hours [1] - The product is characterized by its long duration of action, stable blood concentration without peaks, and smooth glucose control [1]